How to Cite
Abstract
Osteoporosis is a disease characterized by increased bone turnover and decreased bone mass associated with skeletal fragility, which increases the risk of falls and fractures. Inherent in this presentation, osteoporosis is asymptomatic until fractures occur. Currently there is a variety of drugs that can be used in osteoporosis, so it is important to know each one of them and individualize each patient to know when and to whom to provide drug therapy. The most widely used are bone resorption inhibitors, anabolic agents, calcitonin, selective estrogen receptor modulators, and Denosumab. The challenge regarding this pathology is to attract women at high risk in order to establish an early therapy with the aim of preventing fractures.
Keywords
References
Zhu Y, Huang Z, Wang Y, Xu W. The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review. Journal of Orthopaedic Translation. 2020;22:7-9. Available from: https://doi.org/10.1016/j.jot.2019.08.004
Rossi L, Copes R, Dal Osto L, Flores C, Comim F, Premaor M. Factors related with osteoporosis treatment in postmenopausal women. Medicine. 2018;97(28):1-2. Available from: http://dx.doi.org/10.1097/MD.0000000000011524
Anda S, Evija N, Andris A, Una S, Aivars L. Gray values of the cervical vertebrae detected by cone-beam computed tomography for the identification of osteoporosis and osteopenia in postmenopausal women. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021;:4-8. Available from: https://doi.org/10.1016/j.oooo.2021.06.014
Shanks G, Sharma D, Mishra V. Prevention and treatment of osteoporosis in women. OBSTETRICS, GYNAECOLOGY AND REPRODUCTIVE MEDICINE. 2019;29(7):202-204. Available from: https://doi.org/10.1016/j.ogrm.2019.04.001
Rizzoli R. Postmenopausal osteoporosis: Assessment and management. Best Practice & Research Clinical Endocrinology & Metabolism. 2018;32(5):740-741. Available from: https://doi.org/10.1016/j.beem.2018.09.005
Rizzoli, R., Biver, E., Bonjour, JP. et al. Benefits and safety of dietary protein for bone health—an expert consensus paper endorsed by the European Society for Clinical and Economical Aspects of Osteopororosis, Osteoarthritis, and Musculoskeletal Diseases and by the International Osteoporosis Foundation. Osteoporosis International. 2018;29:1933–1948 Available from: https://doi.org/10.1007/s00198-018-4534-5
Bijelic R, Milicevic S, Balaban J. Risk Factors for Osteoporosis in Postmenopausal Women. Med Arch. 2017;71(1):26-27. Available from: https://doi.org/10.5455/medarh.2017.71.25-28
Briot K, Roux C, Thomas T. 2018 update of French recommendations on the management of postmenopausal osteoporosis. Joint Bone Spine. 2018;85(5):521-525. Available from: https://doi.org/10.1016/j.jbspin.2018.02.009
Compston J, Leslie W, McClung M. Osteoporosis. Lancet. 2019;393:364-369.
French K, Emanuele D. Osteoporosis: Increasing Screening and Treatment for Postmenopausal Women. The Journal for Nurse Practitioners. 2019;15(5):349. Available from: https://doi.org/10.1016/j.nurpra.2019.02.014
Compston J, Cooper A, Cooper C. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017;12(1):42-44. Available from: https://doi.org/10.1007/s11657-017-0324-5
Kanis J, Cooper C, Rizzoli R. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International. 2019;30:4-6, 13-15. Available from: https://doi.org/10.1007/s00198-018-4704-5
Arceo-Mendoza R, Camacho P. Postmenopausal Osteoporosis: Latest Guidelines. Endocrinol Metab Clin N Am. 2021;50:167-176. Available from: https://doi.org/10.1016/j.ecl.2021.03.009
Camacho P, Petak S, Binkley N. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/ AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS— 2020 UPDATE. ENDOCRINE PRACTICE. 2020;26(1):5-11. Available from: https://doi.org/10.4158/GL-2020-0524SUPPL
Anastasilakis A, Evangelatos G, Makras P, Iliopoulos A. Rebound-associated vertebral fractures may occur in sequential time points T following denosumab discontinuation: need for prompt treatment re- initiation. Bone Reports. 2020;12:3. Available from: https://doi.org/10.1016/j.bonr.2020.100267
Shoback D, Rosen C, Black D, Cheung A. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update. CLINICAL PRACTICE GUIDELINE UPDATE. 2020;105(3):2-3. Available from: https://doi.org/10.1210/clinem/dgaa048
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2021 Array